Pharma BD Deal Intelligence

Astellas Pharma Inc. / Optimer Pharmaceuticals, Inc.

2012 · Licensing/Option · $90M · Complete

Announcement Sentiment

Strongly positive

Optimer-Astellas exclusive license to develop and commercialize fidaxomicin in Japan for CDI. $20M upfront, up to $70M regulatory/commercial milestones, plus double-digit royalty equivalent on Astellas Japan net sales.

Did it work? Outcome assessment

Strategic verdict

Achieved Stated Rationale

Financial impact

Neutral

Pipeline outcome

Assets Advanced

Assessment window: 10yr post-close.

Key facts

Announced Mar 26, 2012
Closed Mar 26, 2012
Deal value $90M
Deal type Licensing/Option
Therapeutic area Clostridium difficile infection (CDI)
Indications Clostridium difficile infection (CDI)
Key assets Fidaxomicin (Dificid/Dificlir)
Mechanism Macrocyclic antibiotic (RNA polymerase inhibitor)

See the full interactive analysis, sources & comparables →

← Browse all deals · How we score deals